Consistency of atypical antipsychotic superiority to placebo in recent clinical trials
- 1 January 2001
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 49 (1) , 64-70
- https://doi.org/10.1016/s0006-3223(00)00973-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999
- Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboBiological Psychiatry, 1997
- The Rationale and Ethics of Medication-Free Research in SchizophreniaArchives of General Psychiatry, 1997
- ICI 204,636, an Atypical AntipsychoticJournal of Clinical Psychopharmacology, 1996
- Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialPsychopharmacology, 1996
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- The Use of Placebos in Clinical Trials for Acute SchizophreniaThe Canadian Journal of Psychiatry, 1995
- Another view of active-controlled trialsControlled Clinical Trials, 1991
- The Cost of DichotomizationApplied Psychological Measurement, 1983